Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells

Leukemia

Volumn 29, Issue 8, 2015, Pages 1781-1785

  Riether, C ^a   Gschwend, T ^a   Huguenin, A L ^a   Schurch C M ^a   Ochsenbein, A F ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; VIRUS GLYCOPROTEIN; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; IN VIVO STUDY; LETTER; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL THERAPY; C57BL MOUSE; CANCER STEM CELL; CELL CULTURE; CELL PROLIFERATION; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; PATHOLOGY; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84938982075     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.26     Document Type: Letter

References (16)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
2. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513-526.
3. Guzman ML, Allan JN. Concise review: leukemia stem cells in personalized medicine. Stem Cells 2014; 32: 844-851.
4. Riether C, Schürch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ 2014; 22: 187-198.
5. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Rev Immunol 2012; 12: 269-281.
6. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
7. Schürch C, Riether C, Amrein MA, Ochsenbein AF. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-gamma. J Exp Med 2013; 210: 605-621.
8. Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114: 1528-1536.
9. Hobo W, Norde WJ, Schaap N, Fredrix H, Maas F, Schellens K et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J Immunol 2012; 189: 39-49.
10. Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One 2013; 8: e55818.
11. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-197.
12. Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU et al. Altered microenviron-mental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012; 21: 577-592.
13. Ehl S, Hombach J, Aichele P, Rulicke T, Odermatt B, Hengartner H et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8 + T cells to cause immunopathology. J Exp Med 1998; 187: 763-774.
14. Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest 2013; 123: 2654-2662.
15. Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007; 21: 472-479.
16. Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS et al. Characterization of chronic myeloid leukemia stem cells. Am J H1ematol 2011; 86: 31-37.